Ebola & Marburg

Ebola Virus

Scanning electron micrograph of Ebola virus budding from the surface of a Vero cell (African green monkey kidney epithelial cell line).


Scanning electron micrograph of Ebola virus budding from the surface of a Vero cell (African green monkey kidney epithelial cell line).

Credit: NIAID

Ebola virus disease, first recognized in 1976 in the Democratic Republic of the Congo, is a serious and often fatal illness in humans and nonhuman primates. Four of six known virus species of the Ebolavirus genus are known to infect humans and cause Ebola virus disease. They are spread through direct contact with the bodily fluids of a sick person and can cause fever, headache, muscle pain, weakness, fatigue, diarrhea, vomiting, stomach pain and hemorrhage (severe bleeding).

Ebola virus is part of the Filoviridae family, which also includes Marburg virus. Marburg virus disease was first recognized in 1967 and is characterized by the same symptoms and transmission routes as Ebola virus disease. There are two known species of Marburg virus that can cause disease in humans and nonhuman primates.

Why Is the Study of Ebola & Marburg a Priority for NIAID?

Ebola and Marburg viruses are rare but have caused periodic cases and deadly outbreaks in Africa since they were first recognized. The largest outbreak of Ebola virus disease, which occurred in West Africa from 2014 to 2016, caused more than 28,600 infections and more than 11,300 deaths, according to the World Health Organization. There are no licensed treatments or vaccines for Ebola or Marburg virus diseases; however, various experimental countermeasures, including some developed by NIAID, are under evaluation.

How Is NIAID Addressing This Critical Topic?

NIAID researchers and NIAID-supported scientists at external institutions are studying many aspects of the Ebola and Marburg viruses and how they cause disease. This includes seeking better ways to diagnose and treat Ebola virus disease and Marburg fevers and using applied research to develop and test vaccines and treatments.

To learn about risk factors for Ebola and Marburg, as well as learn current prevention and treatment strategies visit the MedlinePlus Ebola site or the visit the Centers for Disease Control and Prevention Marburgh hemorrhagic fever site


NIAID is supporting the development of multiple Ebola vaccine candidates that are in various stages of development. Ebola vaccines are designed to prevent infection.

Read more about Ebola vaccines


NIAID is supporting the development of improved diagnostics to detect Ebola virus infection, including those that can provide rapid identification and can be deployed at the point of care where Ebola virus outbreaks occur. 

Read more about Ebola diagnosis


NIAID is advancing research on several investigational Ebola treatments in different stages of development, including monoclonal antibodies and antivirals.

Read more about Ebola treatment

Researching Ebola in Africa

The 2014-2016 Ebola outbreak in West Africa was the largest recorded in history. As local and international healthcare workers responded to the outbreak, NIAID and the Liberian Ministry of Health established PREVAIL, or the Partnership for Research on Ebola Virus in Liberia. 

Read more about researching Ebola in Africa
Content last reviewed on